Shane J McInerney1,2, Trisha Chakrabarty3, Malgorzata Maciukiewicz4,5, Benicio N Frey6, Glenda M MacQueen7, Roumen V Milev8,9, Arun V Ravindran1, Susan Rotzinger1, Sidney H Kennedy1, Raymond W Lam3. 1. Department of Psychiatry, University of Toronto, Ontario, Canada. 2. Department of Psychiatry, University Hospital Galway, Ireland. 3. Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada. 4. Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada. 5. Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Switzerland. 6. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. 7. Deceased, formerly Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. 8. Department of Psychiatry, Queen's University, Kingston, Ontario, Canada. 9. Department of Psychology, Queen's University, Kingston, Ontario, Canada.
Abstract
OBJECTIVES: Major depressive disorder (MDD) is associated with impairments in both cognition and functioning. However, whether cognitive deficits significantly contribute to impaired psychosocial and occupational functioning, independent of other depressive symptoms, is not well established. We examined the relationship between cognitive performance and functioning in depressed patients before and after antidepressant treatment using secondary data from the first Canadian Biomarker Integration Network in Depression-1 study. METHODS: Cognition was assessed at baseline in unmedicated, depressed participants with MDD (n = 207) using the Central Nervous System Vital Signs computerized battery, psychosocial functioning with the Sheehan Disability Scale (SDS), and occupational functioning with the Lam Employment Absence and Productivity Scale (LEAPS). Cognition (n = 181), SDS (n = 175), and LEAPS (n = 118) were reassessed after participants received 8 weeks of open-label escitalopram monotherapy. A series of linear regressions were conducted to determine (1) whether cognitive functioning was associated with psychosocial and occupational functioning prior to treatment, after adjusting for overall depressive symptom severity and (2) whether changes in cognitive functioning after an 8-week treatment phase were associated with changes in psychosocial and occupational functioning, after adjusting for changes in overall symptom severity. RESULTS: Baseline global cognitive functioning, after adjusting for depression symptom severity and demographic variables, was associated with the SDS work/study subscale (β = -0.17; P = 0.03) and LEAPS productivity subscale (β = -0.17; P = 0.05), but not SDS total (β = 0.19; P = 0.12) or LEAPS total (β = 0.41; P = 0.17) scores. Although LEAPS and SDS scores showed significant improvements after 8 weeks of treatment (P < 0.001), there were no significant associations between changes in cognitive domain scores and functional improvements. CONCLUSION: Cognition was associated with occupational functioning at baseline, but changes in cognition were not associated with psychosocial or occupational functional improvements following escitalopram treatment. We recommend the use of more comprehensive functional assessments to determine the impact of cognitive change on functional outcomes in future research.
OBJECTIVES: Major depressive disorder (MDD) is associated with impairments in both cognition and functioning. However, whether cognitive deficits significantly contribute to impaired psychosocial and occupational functioning, independent of other depressive symptoms, is not well established. We examined the relationship between cognitive performance and functioning in depressed patients before and after antidepressant treatment using secondary data from the first Canadian Biomarker Integration Network in Depression-1 study. METHODS: Cognition was assessed at baseline in unmedicated, depressed participants with MDD (n = 207) using the Central Nervous System Vital Signs computerized battery, psychosocial functioning with the Sheehan Disability Scale (SDS), and occupational functioning with the Lam Employment Absence and Productivity Scale (LEAPS). Cognition (n = 181), SDS (n = 175), and LEAPS (n = 118) were reassessed after participants received 8 weeks of open-label escitalopram monotherapy. A series of linear regressions were conducted to determine (1) whether cognitive functioning was associated with psychosocial and occupational functioning prior to treatment, after adjusting for overall depressive symptom severity and (2) whether changes in cognitive functioning after an 8-week treatment phase were associated with changes in psychosocial and occupational functioning, after adjusting for changes in overall symptom severity. RESULTS: Baseline global cognitive functioning, after adjusting for depression symptom severity and demographic variables, was associated with the SDS work/study subscale (β = -0.17; P = 0.03) and LEAPS productivity subscale (β = -0.17; P = 0.05), but not SDS total (β = 0.19; P = 0.12) or LEAPS total (β = 0.41; P = 0.17) scores. Although LEAPS and SDS scores showed significant improvements after 8 weeks of treatment (P < 0.001), there were no significant associations between changes in cognitive domain scores and functional improvements. CONCLUSION: Cognition was associated with occupational functioning at baseline, but changes in cognition were not associated with psychosocial or occupational functional improvements following escitalopram treatment. We recommend the use of more comprehensive functional assessments to determine the impact of cognitive change on functional outcomes in future research.
Authors: Matthew J Knight; Célia Fourrier; Ellen Lyrtzis; Natalie Aboustate; Emma Sampson; Hikaru Hori; Natalie T Mills; Bernhard T Baune Journal: J Clin Psychiatry Date: 2018-11-20 Impact factor: 4.384
Authors: Bernhard T Baune; Robyn Miller; Jordan McAfoose; Melissa Johnson; Frances Quirk; David Mitchell Journal: Psychiatry Res Date: 2010-04-30 Impact factor: 3.222
Authors: Scott B Patten; Jeanne V A Williams; Dina H Lavorato; Jian Li Wang; Keltie McDonald; Andrew G M Bulloch Journal: Can J Psychiatry Date: 2016-02 Impact factor: 4.356